Association of TCF7L2 rs7903146 Polymorphism with Diabetic Nephropathy in Type 2 Diabetes Mellitus Egyptian Patients

Document Type : Original Article

Authors

1 Internal Medicine Department, Beni-Suef University

2 Clinical and Chemical Department Beni-Suef University.

Abstract

Background: Transcription factor 7-like 2 (TCF7L2) gene polymorphisms are known risk factors for type 2 diabetes mellitus (T2DM). However, the relationship between TCF7L2 polymorphism and diabetic nephropathy (DN) is inconclusive. Objectives: to explore the association of TCF7L2 rs7903146 (C/T) gene polymorphism and DN in T2DM  Egyptian patients. Methods: 80 patients with T2DM (40 patients without DN and 40 patients with DN) were enrolled in the study. Genotyping for the rs7903146 (C/T) polymorphism in TCF7L2 gene was performed by real time PCR.
Results: The frequency of rs7903146 genotypes in diabetic patients without DN was ( CC: 57.5%; CT: 37.5%; TT: 5%), while in diabetic patients with DN was (CC: 2.5%; CT: 40%; TT: 57.5%). Patients with DN were exposed to the TT 25.7 times more than who didn’t develop DN  (OR= 25.7, 95% CI= 0.43-94, P= 0.001**). Upon examining the allelic discrimination, C allele was present in 77.5%  of patients without DN versus 23.8%  of patients with DN, While T allele was found in 22.5%  of patients without DN versus 76.3%  of patients with DN. Patients with DN were exposed to the T allele  11 times more than who didn’t develop nephropathy (OR=11, 95% CI= 5.3-23.1 , P=<0.001**). Conclusion: rs7903146 TCF7L2 gene polymorphism may be significantly associated with the susceptibility to DN in Egyptian T2DM patients.

Keywords

Main Subjects

References

  1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.  Diabetes Res Clin Pract. 2019 Nov;157:107843.
  2. Tong Y1, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B . Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. Review article. BMC Med Genet. 2009 Feb 19;10:15.
  3. Grant SFA. The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes. Diabetes Care. 2019 Sep;42(9):1624-1629.
  4. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018;50:1505–1513.
  5. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007;445:881–885.
  6. Duval A, Busson LM, Berger R. Assignment of the TCF-4 gene (TCF7L2) to human chromosome band 10q25.3. Cytogenet Cell Genet 2000; 88:264–265.
  7. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320–323.
  8. Mitchell RK, Mondragon A, Chen L, et al. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum Mol Genet 2015; 24:1390–1399.
  9. Prunier C, Hocevar BA, Howe PH. Wnt signaling: physiology and pathology. Growth Factors. 2004;22:141–150.
  10. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem. 2005;280:1457–1464.
  11. Wang X, Xiao Y, Mou Y, et al. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res 2002;90:340–7.
  12. Lavoz C, Rayego-Mateos S, Orejudo M, Opazo-Ríos L, et al.  Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy? Review article. J Clin Med. 2020 Jan 19;9(1).
  13. Podgórski P, Konieczny A, Lis Ł, Witkiewicz W, Hruby Z.  Glomerular podocytes in diabetic renal disease.  Adv Clin Exp Med. 2019 Dec;28(12):1711-1715.
  14. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochemical and Biophysical Research Communications. 2013;433:359–361.
  15. Brosius FC, III, Khoury CC, Buller CL, Chen S. Abnormalities in signaling pathways in diabetic nephropathy. Expert Review of Endocrinology and Metabolism. 2010;5(1):51–64.
  16. Tang YL, Dong XY, Zeng ZG, Feng Z. Gene expression-based analysis identified NTNG1 and HGF as biomarkers for diabetic kidney disease. Medicine (Baltimore). 2020 Jan;99(1):e18596.
  17. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26(11): 3160-7.
  18. Pavlov V1, Xiao Y, Gill R, Dishon A, Kotler M, Willner I. Amplified chemiluminescence surface detection of DNA and telomerase activity using catalytic nucleic acid labels. Anal Chem. 2004 Apr 1;76(7):2152-6.
  19. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochemical and Biophysical Research Communications. 2013;433:359–361.
  20. Wang Y, Li H, Song SP. β-Arrestin 1/2 Aggravates Podocyte Apoptosis of Diabetic Nephropathy via Wnt/β-Catenin Pathway. Med Sci Monit. 2018 Mar 24;24:1724-1732.
  21. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/ β-catenin signaling promotes renal interstitial fibrosis. Journal of the American Society of Nephrology. 2009;20(4):765–776.
  22. El-Lebedy D, Ashmawy I.  Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.  J Genet Eng Biotechnol. 2016 Dec;14(2):247-251.
  23. Mandour I, Darwish R, Fayez R, Naguib M, El-Sayegh S. TCF7L2 Gene Polymorphisms and Susceptibility to Type 2 Diabetes Mellitus , A Pilot Study. Biomed Pharmacol J 2018; 11(2): 1043-9.
  24. Zhuang Y, Niu F, Liu D, Sun J, Zhang X, Zhang J, Guo S. Associations of TCF7L2 gene polymorphisms with the risk of diabetic nephropathy: A case-control study. Medicine (Baltimore). 2018 Oct;97(40):e8388.
  25. Fan Z, Cai Q, Chen Y, et al. Association of the Transcription Fac- tor 7 Like 2 (TCF7L2) Polymorphism With Diabetic Nephropathy Risk: A Meta-Analysis. Medicine (Baltimore). 2016; 95(11)e3087.
  26. Hussain H, Ramachandran V, Ravi S, et al. TCF7L2 rs7903146 polymorphism and diabetic nephropathy association is not independent of type 2 diabetes—a study in a south Indian population and meta-analysis. Endokrynol Polska 2014;65:298–305.
  27. Buraczynska M, Swatowski A, Markowska-Gosik D, et al. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and complication/comorbidity profile in type 2 diabetes patients. Diabet Res Clin Pract 2011;93:390–5.
  28. Buraczynska M, Zukowski P, Ksiazek P, et al. Transcription factor 7-like 2 (TCF7L2) gene polymorphism and clinical phenotype in end-stage renal disease patients. Mol Biol Rep 2014;41:4063–8.
  29. Jin T. Current understanding on role of the Wnt signaling pathway effector TCF7L2 in glucose homeostasis. Endocrine reviews 2016; 37: 254-277.
  30. Xiao L, Wang M, Yang S, Liu F, Sun L. A glimpse of the pathogenetic mechanisms of Wnt/β-catenin signaling in diabetic nephropathy.  Biomed Res Int. 2013;2013:987064.
  31. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009 Nov;24(11):3360-6.
  32. Köttgen A, Hwang S-J, Rampersaud E, et al. TCF7L2 variants associate with CKD progression and renal function in population- based cohorts. J Am Soc Nephrol. 2008; 19(10): 1989- 99.
  33. Takada I, Makishima M. Peroxisome proliferator-activated receptor agonists and antagonists: a patent review (2014-present). Review article. Expert Opin Ther Pat. 2020 Jan;30(1):1-13.
  34. Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, Papanas N, Manolopoulos VG, Chatzaki E. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. Exp Clin Endocrinol Diabetes. 2019 Apr;127(4):226-233.

Files

Share

How to cite

Statistics